"Thrilled to present this phase 1 of lefitolimod (TLR9 agonist) plus ipilimimab in refractory advanced tumors. It was safe and well tolerated and we expect maybe other combinations will improve the efficacy! Why not anti-PD1/L1? @DavidHongMD @JIPOEditors" (,@mirella_nardo) Jun 4, 2023
Clinical • Metastases • P1 data • Oncology
|